Robert J. Motzer, MD, on Phase III Results of CheckMate 025 Nivolumab vs Everolimus in Advanced RCC
2015 European Cancer CongressRobert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses the results of this study, which could well change the treatment paradigm in patients with previously treated metastatic renal cell carcinoma (Abstract 3LBA).
Related Videos
Martine Frouws, MSc, PhD, on Postdiagnosis Aspirin and Improved Survival in All GI Cancers
Martine Frouws, MD, PhD Candidate, of Leiden University Medical Centre discusses her study, which showed a significant increase in overall survival among patients with GI cancers w...
Martine J. Piccart-Gebhart, MD, PhD, on New Frontiers in Imaging
Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, and ECCO President, discusses ways in which imaging can form the solution to individualized cancer treatment.
Michel Ducreux, MD, PhD, on Results of the Phase II COLO 001 Clinical Trial
Michel Ducreux, MD, PhD, of the Institut Gustave Roussy, discusses the efficacy and safety in this study of nab-paclitaxel in patients with previously treated metastatic colorectal...
A. Oliver Sartor, MD, on Results of the ALSYMPCA Trial for Castration-Resistant Prostate Cancer
A. Oliver Sartor, MD, of Tulane University School of Medicine, discusses the latest results of a clinical trial on radium-223 dichloride and the improvement in overall survival of ...
Jean-Charles Soria, MD, PhD, on Results of the Lux Lung 8 Clinical Trial
Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: afatinib vs erlotinib in squamous cell carcinoma of the lung.
